These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 19559112

  • 1. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
    Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS.
    Vaccine; 2009 Aug 13; 27(37):5142-51. PubMed ID: 19559112
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.
    Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP.
    Gastroenterology; 2008 May 13; 134(5):1385-95. PubMed ID: 18471515
    [Abstract] [Full Text] [Related]

  • 3. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.
    Schlaphoff V, Klade CS, Jilma B, Jelovcan SB, Cornberg M, Tauber E, Manns MP, Wedemeyer H, IC41 Study Group.
    Vaccine; 2007 Sep 17; 25(37-38):6793-806. PubMed ID: 17686555
    [Abstract] [Full Text] [Related]

  • 4. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.
    Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, Dusheiko G, Klenerman P.
    Hepatology; 2002 Sep 17; 36(3):743-54. PubMed ID: 12198669
    [Abstract] [Full Text] [Related]

  • 5. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy.
    Yutani S, Yamada A, Yoshida K, Takao Y, Tamura M, Komatsu N, Ide T, Tanaka M, Sata M, Itoh K.
    Vaccine; 2007 Oct 16; 25(42):7429-35. PubMed ID: 17845828
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.
    Firbas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B, Klade CS.
    Vaccine; 2010 Mar 11; 28(12):2397-407. PubMed ID: 20060945
    [Abstract] [Full Text] [Related]

  • 7. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.
    Smyk-Pearson S, Tester IA, Lezotte D, Sasaki AW, Lewinsohn DM, Rosen HR.
    J Infect Dis; 2006 Aug 15; 194(4):454-63. PubMed ID: 16845628
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.
    Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS.
    Vaccine; 2006 May 15; 24(20):4343-53. PubMed ID: 16581161
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effect of controlled therapy interruption in chronic HCV infection: enhanced host immune response? A hypothesis.
    Lake-Bakaar G.
    J Clin Virol; 2009 Feb 15; 44(2):149-51. PubMed ID: 19157972
    [Abstract] [Full Text] [Related]

  • 15. Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.
    Mariano A, Caserta C, Pendino GM, Vacalebre C, Surace P, Fiorillo MT, Polito I, Surace M, Alicante S, Amante A, Foti G, Marra M, Gutamo G, Amato F, Messineo A, Mele A.
    Dig Liver Dis; 2009 Jul 15; 41(7):509-15. PubMed ID: 19196557
    [Abstract] [Full Text] [Related]

  • 16. HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection.
    Denholm JT, Wright EJ, Street A, Sasadeusz JJ.
    Haemophilia; 2009 Mar 15; 15(2):538-43. PubMed ID: 19187189
    [Abstract] [Full Text] [Related]

  • 17. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M, Marusawa H, Yamada R, Nasu A, Osaki Y, Kudo M, Nabeshima M, Fukuda Y, Chiba T, Matsuda F.
    J Viral Hepat; 2009 Jun 15; 16(6):388-96. PubMed ID: 19200137
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro activation and differentiation of naïve CD4+ and CD8+ T cells into HCV core- and NS3-specific armed effector cells: a new role for CD4+ T cells.
    Krishnadas DK, Li W, Kumar R, Tyrrell LJ, Agrawal B.
    Cell Immunol; 2009 Jun 15; 259(2):141-9. PubMed ID: 19616202
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.